ViroStatics srl is dedicated to develop drugs to overcome the underlying cellular perturbations common to cancer and viral diseases - dysregulation of cellular transcription and uncontrolled cell proliferation. To this end, ViroStatics has focused on selectively targeting the Cyclin Dependent Kinases (CDKs) involved in these perturbations (CDK9 and CDK4/6).
Contents
History
ViroStatics was formed In 2007 as a for-profit spin-off from the Research Institute for Human and Genetic Therapy (RIGHT), a US-based 501(c)3 corporation pursuing innovative antiviral therapies and vaccine research. Led by CEO Franco Lori, MD, PhD, ViroStatics has its corporate headquarters in Sassari (Sardinia) Italy, R&D laboratories in the Science and Technology Park of Sardinia (Sardegna Ricerche) in Alghero (Sardinia) and Business Development offices in North America.
Drugs
ViroStatics has discovered and is developing novel, highly potent inhibitors, which selectively target CDK4/6/9 in a single molecule for a multifaceted approach for the durable treatment of cancers and viral diseases.
The Company has developed a robust pipeline of proprietary compounds, with patent protection beyond 2030, for a number of distinct disease indications.
VIRAL DISEASE PROGRAM: ViroStatics’ unique multifaceted compounds offer the potential for a paradigm shift in the treatment of viral diseases
ONOCOLOGY PROGRAM: Designed to Address the Unmet Medical Need for Durable Treatment for Cancers